Abstract:BACKGROUND: Edaravone can alleviate brain injury and improve neurological functions and symptoms. This study aimed to investigate the effect of edaravone on the p38Mitogen-activated protein kinases/Caspase-3 (p38MAPK /Caspase-3) pathway after diffuse brain injury (DBI) in rats.METHODS: DBI models were established according to the description of Marmarou's method. A total of 250 rats were divided (random number) into four groups: control group (CG, n=45), model group (MG, n=77), low-dose edaravone group (n=67, dosage 5 mg/kg) and high-dose edaravone group (n=61, dosage 10 mg/kg). After 1, 6, 24, 48, and 72 hours after injury, brain tissues were collected. The changes of neuron morphous in the hippocampal region were observed through Nissl staining. The expression levels of phosphorylated p38MAPK and caspase-3 were detected by immunohistochemistry and Western blotting respectively. Learning and memory function were tested with Morris water maze from the 3rd to 7th day after injury.RESULTS: Some neurons had histopathologic changes of necrosis and apoptosis in the model group compared with the control group. The phosphorylated p38MAPK expressions increased at 1, 6, 4, and 48 hours (P<0.05), but no significant difference was observed at 72 hours (0.54 +/- 0.19 vs. 0.40 +/- 0.14, P>0.05). Caspase-3 expressions increased at 6, 24, 48, and 72 hours respectively (P<0.05), but there was no significant difference at 1 hour (0.59 +/- 0.29 vs. 0.40 +/- 0.17, P>0.05). From the 3rd to 6th day during the Morris water maze test, the latency to find the platform was significantly prolonged (P<0.05) and times of rats crossing the platform was decreased on the 7th day (2.28 +/- 1.18 vs. 8.20 +/- 1.52, P<0.05). The phosphorylated p38MAPK expressions decreased at 6, 24 and 48 hours respectively in the low dose edaravone group compared with the model group (P<0.05), whereas no significant difference was seen at 1 hour (1.66 0.80 vs. 1.85 +/- 0.86, P>0.05). Caspase-3 expression decreased at 6, 24, 48, and 72 hours (P<0.05). The latency to find the platform was significantly shortened (P<0.05), and times of rats crossing the platform increased (4.17 +/- 1.15 vs. 2.28 1.18, P<0.05). The above mentioned parameters changed more significantly in the high-dose edaravone group than in the low-dose edaravone group.CONCLUSION: Edaravone can alleviate brain tissue damage after DBI, inhibit p38MAP signal activation after early injury, reduce the expression of caspase-3, and promote the recovery of neurological function in the late period.

The protection of edaravone against 1-bromopropane damaged mitochondrial complex of prefrontal cortex in rats

Neuroprotective effect of edaravone on focal cerebral ischemia in rats

Abstract T P84: Neuroprotective Effect of Probenecid in a Rat Model of Transient Global Cerebral Ischemia-Reperfusion

Protective Effects of Edaravone on Renal Ischemia-Reperfusion Injury in Rats

Effect of edaravone against oxidative damage caused by acute craniocerebral trauma

Protective Effects of Edaravone on Diffuse Brain Injury in Rats

Edaravone Protects PC12 Cells from Ischemic-Like Injury Via Attenuating the Damage to Mitochondria

Protective Effect of Edaravone on Ventilator Induced Lung Injury in Rats

Edaravone alleviated propofol‐induced neural injury in developing rats by BDNF/TrkB pathway

Edaravone Protects Cortical Neurons from Apoptosis by Inhibiting the Translocation of Bax and Increasing the Interaction Between 14-3-3 and P-Bad

Metabolomic Profiling of Brain Protective Effect of Edaravone on Cerebral Ischemia-Reperfusion Injury in Mice

Edaravone Protects Primary-Cultured Rat Cortical Neurons from Ketamine-Induced Apoptosis Via Reducing Oxidative Stress and Activating PI3K/Akt Signal Pathway

Edaravone dexborneol protects against cerebral ischemia/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of nrf-2/HO-1/GPX4 signaling

Edaravone Dexborneol provides neuroprotective effect by inhibiting neurotoxic activation of astrocytes through inhibiting NF-κB signaling in cortical ischemia

Edaravone Alleviated Propofol-Induced Neurotoxicity in Developing Hippocampus by Mbdnf/trkb/pi3k Pathway

Edaravone protects against methylglyoxal-induced barrier damage in human brain endothelial cells

Neuroprotection of Oral Edaravone on Middle Cerebral Artery Occlusion in Rats

Protective Effect of Edaravone in Primary Cerebellar Granule Neurons against Iodoacetic Acid-Induced Cell Injury

Targeted Therapy of Ischemic Stroke Via Crossing the Blood-Brain Barrier Using Edaravone-Loaded Multiresponsive Microgels.

Protective Effect of Edaravone on Free Radical Reaction after Cerebral Hemorrhage

Edaravone Plays Protective Effects on LPS-Induced Microglia by Switching M1/M2 Phenotypes and Regulating NLRP3 Inflammasome Activation